Twice daily tripotassium dicitrato bismuthate in the treatment of duodenal ulceration

David Hollanders

Department of Medicine, University Hospital of South Manchester, Manchester M20, UK.

Summary: Fifty three patients with endoscopically proven duodenal ulceration have cooperated in a clinical trial to compare the ulcer healing effect of tripotassium dicitrato bismuthate (TDB) at standard dosage administered either twice or four times daily. No statistically significant difference has been found to exist between ulcer healing in the two groups at 4 weeks (72% and 67%, $P = 0.944$) or at 8 weeks (92% and 81%, $P = 0.504$) and it is concluded that twice daily TDB maintains the effectiveness of the drug and has advantages for patient compliance.

Introduction

Tripotassium dicitrato bismuthate (TDB) in both liquid (Martin et al., 1981; Shreeve et al., 1983) and tablet form (Vantruppen et al., 1980; Moskal et al., 1981) has been shown to heal duodenal ulceration as effectively as cimetidine. However, while the trend for some other ulcer healing drugs, particularly the H₂ antagonists, has been to move to a twice or single daily dose it is recommended by the manufacturers of TDB (Gist Brocades) that the drug be given four times daily. This increases inconvenience of use and interferes with patient compliance. The present single-blind study has been designed to compare TDB tablets given four times daily with a twice daily regime in the healing of duodenal ulcer.

Patients and methods

Fifty three patients were enrolled into the trial and assigned randomly to receive TDB chewable tablets one four times daily (QDS group) or two twice daily (BD group). Each tablet contained 120 mg tripotassium dicitrato bismuthate. At the end of the study there had been seven withdrawals leaving 21 patients in the QDS group and 25 patients in the BD group for analysis. The groups were well matched for age, duration of ulcer disease, length of current relapse, smoking and drinking habits. No statistically significant difference ($t$ test) for any of the parameters was found (Table 1).

Before entry to the trial all patients had endoscopically proven duodenal ulceration, had given their informed consent and had used no ulcer healing or ulcerogenic drugs in the preceding 2 weeks. In all cases treatment commenced on the same day as the diagnostic endoscopy. Antacids of their choice were allowed as required and patients were asked not to change their drinking or smoking habits for the duration of the study. Patients specifically excluded were any who had previously undergone upper gastrointestinal surgery or who suffered from debilitating conditions likely to interfere with tissue healing.

Initially treatment was given for 4 weeks and followed by a check endoscopy. If healing had not taken place a further 4 week course of medication at the same dosage frequency was provided and a third endoscopy carried out 8 weeks after entry. Any cases not having healed at this stage were withdrawn and placed on alternative ulcer-healing drugs. Information on side effects was requested at each visit for repeat endoscopy. Blood for the estimation of bismuth levels was obtained at entry and repeated at 4 weeks. In those cases still on treatment a further sample was taken at 8 weeks.

Results

Ulcer healing

The results show that after 4 weeks of treatment 14 of 21 cases (67%) (95% confidence limits = 43–85%) healed in the group given tablets four times daily and 18 of 25 (72%) (95% confidence limits = 51–88%) among those receiving medication twice daily. Those who failed to heal at 4 weeks received a further course

Correspondence: D. Hollanders, M.Sc., M.R.C.P.
Accepted: 7 August 1985

© The Fellowship of Postgraduate Medicine, 1986
of identical treatment bringing the healing rates at 8 weeks to 17 (81%) (95% confidence limits = 58–95%) in the QDS group and 23 (92%) (95% confidence limits = 74–99%) in the BD group. Two patients in the QDS group failed to attend for their final endoscopy at 8 weeks and for the purposes of analysis the healing rate of 81% is based on the assumption that neither of these two cases were healed.

Using the Chi square test no statistically significant difference exists between ulcer healing rates in the two groups at 4 weeks (P = 0.944) or at 8 weeks (P = 0.504) though numerically the trend may be in favour of the twice daily dosage.

**Bismuth levels**

Serum bismuth levels were measured in the first 30 patients enrolled in the trial. These consisted of 14 and 16 cases from the QDS and BD groups respectively. Mean bismuth levels at 4 and 8 weeks were 10 µg/l and 10 g/l respectively for the group receiving TDB four times daily and 13 µg/l and 12 µg/l for those given TDB twice daily. The highest single concentration recorded was 30 µg/l in a patient after 4 weeks’ treatment in the BD group. All measurements were well below the therapeutically acceptable upper limit of 50 µg/l (Hillemand et al., 1977).

**Side effects**

No clinically significant side effects were encountered. The commonest complaint was of a mild and temporary blackish discoloration of the tongue which occurred in 8 cases in the QDS group and 9 cases in the BD group. No patient considered this an unacceptable problem and in no case was discontinuation of the medication required because of it. Other side effects reported were of an unpleasant lingering taste after chewing the tablets (one complaint from each group) and one instance of flatulent dyspepsia after the tablets in the BD group.

**Withdrawals**

Seven patients were withdrawn during the course of the trial, five of these being from the QDS group. Non-compliance with dosage requirements resulted in five withdrawals (four from the QDS and one from the BD group) while a further two cases (one from each group) needed urgent surgery, one for bleeding and the other for pyloric stenosis.

**Discussion**

This study shows TDB chewable tablets given twice daily to be as effective as the equivalent dose administered four times daily in the healing of duodenal ulcers. The rate of healing observed at 4 weeks (72%) and 8 weeks (92%) in the group given treatment twice daily is comparable with that previously reported for TDB (66% at 4 weeks and 89% at 8 weeks) and cimetidine (60% at 4 weeks and 85% at 8 weeks) (Martin et al., 1981). No adverse effects peculiar to the twice daily TDB regime were encountered.

These results are of some interest in relation to the proposed mode of action of TDB. It is generally suggested that this drug acts as a mucosal protectant but how this is achieved is unknown. Direct shielding of the ulcer surface from acid and peptic digestion by adherence of the bismuth salt has been suggested by Koo et al. (1982) who were able to show the adherence of bismuth to the surface of experimental gastric ulcer in rats by histochemical means but not macroscopically. Staining was prominent only in animals killed 1 to 2 hours after ingestion of TDB and much less evident thereafter. The idea of a short-lived physical barrier over the ulcer surface producing the healing effect of TDB is not appealing but may have some merit if the barrier is renewed four times daily as with conventional dosage frequency. However, such a proposed mechanism of action seems much less likely when twice daily administration produces the same healing effect. If the bismuth attached to the ulcer surface is important then it probably does not act as a simple mechanical barrier against acid and pepsin.

Other suggested modes of action for TDB include a regenerative affect on the microvilli of duodenal mucosal cells (Moshol et al., 1979) and the possibility that TDB encourages the return of gastric mucus

---

**Table 1** Patient details in those given TDB tablets four times daily (QDS group) or twice daily (BD group). Where appropriate mean values are presented followed by the range in brackets.

<table>
<thead>
<tr>
<th></th>
<th>No. cases</th>
<th>Female</th>
<th>Age (y)</th>
<th>Ulcer duration (y)</th>
<th>Duration present relapse (months)</th>
<th>Smoking (cigs/day)</th>
<th>Alcohol (drinks/week)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>QDS group</strong></td>
<td>21</td>
<td>9</td>
<td>48</td>
<td>3.7</td>
<td>6</td>
<td>10</td>
<td>6.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(19–75)</td>
<td>(0.5–15)</td>
<td>(3–24)</td>
<td>(0–30)</td>
<td>(0–50)</td>
</tr>
<tr>
<td><strong>BD group</strong></td>
<td>25</td>
<td>4</td>
<td>50</td>
<td>6.2</td>
<td>5.1</td>
<td>12</td>
<td>6.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(17–79)</td>
<td>(0.25–30)</td>
<td>(3–12)</td>
<td>(0–40)</td>
<td>(0–35)</td>
</tr>
</tbody>
</table>
towards a normal quality and quantity during ulcer healing. Such an effect has been demonstrated for gastric ulcer treated by TDB (Hollanders et al., 1983). How such actions are produced by the drug are entirely unclear and hence there are no theoretical reasons why a twice daily dosage should not be as effective as four times per day.

On the basis of our results it is concluded that TDB administered twice daily is an effective treatment for duodenal ulcer. This reduced frequency of administration, brings bismuth subcitrate therapy into line with the dosage frequency of other ulcer healing medicaments and is likely to increase both compliance with and patient acceptability of this drug.

Acknowledgements

We are grateful to Brocades (GB) Ltd. for supplying the trial materials and to Mrs M. Williamson for typing the manuscript.

References


Twice daily tripotassium dicitrato bismuthate in the treatment of duodenal ulceration.
D. Hollanders

Postgrad Med J 1986 62: 19-21
doi: 10.1136/pgmj.62.723.19

Updated information and services can be found at:
http://pmj.bmj.com/content/62/723/19

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/